Mr Mark Charest, PhD

KANDO id: 86191

Bio

Mark joined Panorama Capital in 2010 as an Associate and Kauffman Fellow focusing on life sciences investments. Mark was previously employed by ZS Associates, a healthcare-focused management consultancy, where he led sales and marketing engagements for a variety of global pharmaceutical companies. Mark developed a passion for life sciences investing as an Associate at Great Point Partners, a healthcare-focused investment firm. In this role, he sourced and managed capital allocations in public and private therapeutics companies across all disease areas. Prior to Great Point, he played a leadership role in several drug discovery programs in the oncology area as a medicinal chemistry lab manager at Novartis Institutes for BioMedical Research in Cambridge, MA. He is currently on the board of Itero Biopharmaceuticals and a board observer of Presidio Pharmaceuticals and PowerVision. Mark holds a Ph.D. in Chemistry and Chemical Biology from Harvard University, a M.S. in Chemistry and Chemical Biology from Harvard University and a B.A. in Chemistry with the highest honors from Rutgers University. During his graduate studies, Dr. Charest completed the chemical synthesis of (-)-tetracycline and made key contributions to intellectual property out-licensed to found Tetraphase Pharmaceuticals.

Education